Quidel Molecular Direct C. difficile
For the qualitive detection and identification of toxigenic Clostridium difficle bacterial DNA using real time PCR
- <70-minute turn-around time from sample to result.
- 3-step sample preparation
- No heat step
- No timed step
- No vortexing or centrifugation
- Nucleic acid amplification tests can be as much as twice as sensitive as enzyme immunoassays.1
- Increasing rates of commmunity-acquired C. difficile.2
- C. difficile infection (CDI) can range in severity from asymptomatic to life-threatening, especially among the elderly (most often nosocomially infected in hospitals, nursing homes or other medical institutions).3
- Relapses of C. difficile have been reported in up to 20% of cases.4 Increases to 40% and 60% with subsequent recurrences.5
- C. difficile infection often mimics some flu-like symptoms and can mimic disease flare in patients with inflammatory bowel disease associated colitis.6
|M105||96 tests||Assay Kit|
(required for M105)
|96 samples||Sample Prep Kit|
|M108||2 mL||Control Kit|
|Also available through Life Technologies.|
1Howell MD, Novack V, Grgurich P et al. Latrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch. Intern. Med. May 2010:170 (9):784-90.
2Clabots CR, Johnson S, Olson MM, Peterson LR, Gering DN. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J. Infect Dis. Sept 1992:166 (3):561-7.
3Ryan KJ, CG (ed). Sherris Medical Microbiology (4th ed.) McGraw Hill. pp. 322-4.
4Kelly CP, LaMont JT. Clostridium difficile-more difficult than ever. N. Engl. J. Med. Oct 2008:359 (18): 1932-40.